Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mural Oncology plc - Ordinary Shares (NQ: MURA )

3.150 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.150
Bid (Size) 3.000 (3)
Ask (Size) 4.510 (10)
Prev. Close 3.150
Today's Range 3.150 - 3.150
52wk Range 2.880 - 17.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mural Oncology to Present at Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-47.32%
-47.32%
1 Month
-6.80%
-6.80%
3 Month
-5.97%
-5.97%
6 Month
-41.23%
-41.23%
1 Year
-17.11%
-17.11%

More News

Read More
MURA Stock Earnings: Mural Oncology Beats EPS for Q2 2024
Via InvestorPlace
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
From Mural Oncology, Inc.
Via GlobeNewswire
MURA Stock Earnings: Mural Oncology Reported Results for Q1 2024
Via InvestorPlace
MURA Stock Earnings: Mural Oncology Reported Results for Q4 2023
Via InvestorPlace
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in January
Via InvestorPlace
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
From Mural Oncology, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.